The use of radiolabeled antibodies that are able to target primary tumors as well as metastatic tumor sites with minimal reactivity to normal tissues is a promising approach for treating pancreatic cancer. In this study, the integrin alpha(v)beta(5) is studied as a target for the diagnosis of and potential therapy for human pancreatic cancer by using the radiolabeled murine monoclonal antibody (mAb) 14C5. Biopsy specimens from human pancreatic tumors were examined for the expression of the integrin alpha(v)beta(5). The pancreatic tumor cell line Capan-1 was used to test the in vitro targeting potency of mAb 14C5 labeled with 125/131-iodine and 111-indium. Internalization, retention, and metabolism were investigated in cellular radioimmunoas...
Background: Mesothelin (MSLN) is a tumor differentiation antigen that is highly expressed by cells o...
Accurately identifying metastatic disease is critical to directing the appropriate treatment in panc...
The poor prognosis of pancreatic cancer requires the development of more effective therapy. CD147 ex...
The use of radiolabeled antibodies that are able to target primary tumors as well as metastatic tumo...
The use of radiolabeled antibodies that are able to target primary tumors as well as metastatic tumo...
INTRODUCTION: \nPancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore,...
PURPOSE: The monoclonal antibody (mAb) 14C5 is a murine IgG1 directed against a yet undefined molecu...
Background: Pancreatic cancer is a challenging malignancy in term of its less specific symptoms, lat...
Aim: Pancreatic cancer (PC) remains one of the deadliest cancers with very poor prognosis. New effec...
Pancreatic cancer is the 12th most common diagnosed cancer and the 7th leading cause of cancer death...
Purpose: The aim of this study was to investigate the effect of targeted alpha therapy for the contr...
Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of m...
Background: Mesothelin (MSLN) is a tumor differentiation antigen that is highly expressed by cells o...
Background: Mesothelin (MSLN) is a tumor differentiation antigen that is highly expressed by cells o...
To explore suitable imaging probes for early and specific detection of pancreatic cancer, we demonst...
Background: Mesothelin (MSLN) is a tumor differentiation antigen that is highly expressed by cells o...
Accurately identifying metastatic disease is critical to directing the appropriate treatment in panc...
The poor prognosis of pancreatic cancer requires the development of more effective therapy. CD147 ex...
The use of radiolabeled antibodies that are able to target primary tumors as well as metastatic tumo...
The use of radiolabeled antibodies that are able to target primary tumors as well as metastatic tumo...
INTRODUCTION: \nPancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore,...
PURPOSE: The monoclonal antibody (mAb) 14C5 is a murine IgG1 directed against a yet undefined molecu...
Background: Pancreatic cancer is a challenging malignancy in term of its less specific symptoms, lat...
Aim: Pancreatic cancer (PC) remains one of the deadliest cancers with very poor prognosis. New effec...
Pancreatic cancer is the 12th most common diagnosed cancer and the 7th leading cause of cancer death...
Purpose: The aim of this study was to investigate the effect of targeted alpha therapy for the contr...
Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of m...
Background: Mesothelin (MSLN) is a tumor differentiation antigen that is highly expressed by cells o...
Background: Mesothelin (MSLN) is a tumor differentiation antigen that is highly expressed by cells o...
To explore suitable imaging probes for early and specific detection of pancreatic cancer, we demonst...
Background: Mesothelin (MSLN) is a tumor differentiation antigen that is highly expressed by cells o...
Accurately identifying metastatic disease is critical to directing the appropriate treatment in panc...
The poor prognosis of pancreatic cancer requires the development of more effective therapy. CD147 ex...